Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — Kim YI et al. — H. pylori Eradication, Gastric Atrophy/IM (PMID 42141842)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Extends the landmark 2018 NEJM RCT with long-term histological data (median 5.9y); OR 5.81 for atrophy improvement is a meaningful quantitative advance over prior short-term data |
| Clinical Relevance | 9 | Directly validates sustained benefit of eradication in post-endoscopic resection patients; informs surveillance intervals and eradication timing in clinical practice globally |
| Population Reach | 7 | Gastric cancer is the 5th most common cancer worldwide; high-prevalence regions (East Asia, Latin America, Eastern Europe) have millions of high-risk patients |
| Implementation Speed | 9 | H. pylori eradication therapy is already standard practice; findings strengthen and extend existing recommendations with no new infrastructure needed |
| Evidence Strength | 8 | Long-term follow-up of an RCT (highest feasible design for this question); 327/470 participants retained; abstract-only limits full methodology assessment |
Key quantitative result: OR 5.81 for gastric atrophy improvement; OR 3.23 for intestinal metaplasia; concordant OLGA/OLGIM staging improvements.
External validation: This IS the validation — it is a long-term follow-up of the original 2018 NEJM RCT (Lee et al.). The parent trial already replicated and established eradication benefit; this confirms durability.
Main limitation: Abstract only; open-label design; 30% attrition from original 470; follow-up endpoint is histological surrogate (cancer incidence data not yet available from this analysis).
Equity implications: Findings are most impactful in East Asia, Latin America, and developing nations where both H. pylori prevalence and gastric cancer mortality are highest and where endoscopic surveillance resources are strained. Benefits may reach underserved populations if eradication programs are scaled; disparities in access to endoscopy limit full implementation in low-resource settings.
Evidence Maturity: ✅ Confirmed — Validated
Article 2 — Lansu J et al. — DOREMY Trial, Myxoid Liposarcoma RT (PMID 42141895)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Dose reduction of 28% (36 vs 50 Gy) with maintained local control in a radiation-sensitive sarcoma subtype; challenges historical standard; one of the largest prospective series in this rare cancer |
| Clinical Relevance | 8 | Directly practice-relevant for radiation oncologists managing myxoid liposarcoma; reduces toxicity burden with no apparent oncological compromise |
| Population Reach | 4 | Rare cancer — myxoid liposarcoma comprises ~5% of all soft tissue sarcomas; ~500–800 new cases/year in the US. Scored relative to high unmet need in this population |
| Implementation Speed | 6 | Phase 2 non-randomized; authors explicitly advocate adoption given impossibility of phase 3; expert centers could implement within 1–3 years but broader adoption requires guideline uptake |
| Evidence Strength | 7 | Prospective multicenter (9 centers, EU+US), 10-year enrollment, median 66.4-month follow-up, NCT registered; single-arm design is a limitation but is the best feasible for this indication |
Key quantitative result: 5-year LRFS 97.4%, 5-year OS 88.5%, wound complications 21%, grade ≥3 late toxicity 3%.
External validation: No direct randomized comparator; historical benchmarking against 50 Gy series is implied. Independent external replication not yet available.
Main limitation: Single-arm design with no concurrent control group; selection bias possible at expert sarcoma centers; abstract only reviewed.
Equity implications: Concentration at 9 high-volume tertiary sarcoma centers in Europe and the US means findings are immediately applicable mainly in well-resourced settings. Patients in lower-resource or non-specialist centers may not benefit promptly. Rare disease designation compounds access inequity.
Evidence Maturity: ✅ Confirmed — Potentially Practice-Changing
Article 3 — Croci R et al. — Influenza Vaccination, AMI/Stroke Risk (PMID 42141868)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | The influenza-CV link is established, but quantification of vaccine attenuation effect using a robust SCCS design with 11-year national data and interaction testing is a meaningful methodological and evidence advance |
| Clinical Relevance | 8 | Directly reinforceable in cardiology and primary care; reframes influenza vaccine as cardioprotective intervention; interaction p=0.020 for vaccine attenuation adds precision |
| Population Reach | 9 | Adults ≥40 with cardiovascular risk represent hundreds of millions globally; annual influenza vaccination is a universal public health touchpoint |
| Implementation Speed | 9 | No new treatment or infrastructure required; findings support enhanced messaging in existing vaccine programs immediately |
| Evidence Strength | 8 | SCCS design controls for time-invariant confounders; full national registry (11-year span); PCR-confirmed influenza (not self-report); conditional Poisson regression; abstract only limits full assessment |
Key quantitative result: AMI IRR 4.7x, stroke IRR 2.9x in 7-day post-influenza window; vaccine attenuation of cardiovascular risk significant (interaction p=0.020).
External validation: Prior SCCS studies (Kwong et al. 2013, Udell et al. meta-analysis) support the association; this study adds vaccine attenuation evidence with a longer and more recent data window.
Main limitation: SCCS design cannot fully exclude residual confounding; vaccine type/formulation effects not disaggregated; n=1,221 limits subgroup precision; abstract only reviewed.
Equity implications: Median cohort age ~75 years. Older adults, those with existing cardiovascular disease, and lower-income populations with historically lower vaccination rates stand to gain the most — but are also often the least consistently vaccinated. Findings provide a compelling equity-relevant argument for targeted vaccine outreach to these groups.
Evidence Maturity: ✅ Confirmed — Validated
Article 4 — Schmetz A et al. — COVID-19 Vaccination, ROUTINE-COV19 (PMID 42141891)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Real-world endemic-phase COVID vaccine effectiveness is increasingly documented; the long COVID reduction (RR 0.43) and mortality reduction (HR 0.76) add to a growing body but are not methodologically unprecedented |
| Clinical Relevance | 8 | 57% long COVID reduction and 59% hospitalization reduction are clinically significant; supports ongoing national vaccination programs with quantified benefit during endemic circulation |
| Population Reach | 9 | All adults in countries with COVID-19 circulation; most directly applicable to Europe and high-income nations with similar healthcare structures |
| Implementation Speed | 8 | Vaccine programs exist; findings enhance the policy rationale for continuation; rapid uptake into public health guidance is feasible |
| Evidence Strength | 6 | Large propensity-matched cohort (n=146,132) is a strength; retrospective observational design with residual confounding risk; ⚠️ industry COI noted — BioNTech/Pfizer co-authorship and likely funding; geographic restriction to two German states (Saxony + Thuringia) limits generalizability |
Key quantitative result: RR 0.43 for long COVID, RR 0.41 for COVID-19-related hospitalization, HR 0.76 for all-cause mortality.
External validation: Consistent with prior effectiveness studies in the endemic phase; propensity matching strengthens internal validity; COI warrants independent replication before guideline reliance.
Main limitation: Industry co-authorship (BioNTech/Pfizer); retrospective; two German states only; all-cause mortality reduction requires careful interpretation (healthy vaccinee bias possible despite PSM); abstract only.
Evidence Maturity: ✅ Confirmed — Validated (with COI caveat reducing confidence weight)
Article 5 — Goodall E et al. — DLBCL Trial Eligibility (PMID 42141736)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Systematic quantification of eligibility gaps across 7 registrational trials in a single real-world cohort, combined with the survival equivalence finding, is a meaningful contribution to trial design discourse |
| Clinical Relevance | 7 | Directly relevant to hematologists, trial designers, and regulators; 52% ineligibility with no survival disadvantage challenges the construct validity of current exclusion criteria |
| Population Reach | 6 | DLBCL is the most common aggressive lymphoma (~25,000 new US cases/year); global relevance for a major hematologic malignancy |
| Implementation Speed | 5 | Requires regulatory and sponsor-level changes to trial design; slower implementation pathway, though individual centers can review local practice now |
| Evidence Strength | 6 | Australian registry with 180 patients and 320 relapses; multicenter; retrospective; no causal inference on outcomes; eligibility mapping approach is robust but cohort size limits power |
Key quantitative result: Trial eligibility 4–22% (range across 7 trials); 52% ineligible for all trials; no OS difference between eligible vs ineligible patients.
External validation: No external replication yet; consistent with broader literature on real-world vs trial population mismatches.
Main limitation: Retrospective; single-country (Australia); small cohort for subgroup analysis; abstract only.
Equity implications: Patients excluded from trials may disproportionately include older adults, those with comorbidities, and patients from underrepresented settings. The survival equivalence finding argues for broadening eligibility criteria, which would most benefit these systematically excluded groups.
Evidence Maturity: ✅ Confirmed — Validated
Article 6 — Chen W et al. — ICI Sequencing in Stage III NSCLC (PMID 42141789)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | The question of ICI sequencing in stage III NSCLC is under active study; this adds real-world PSM data but is not a paradigm-shifting design |
| Clinical Relevance | 7 | Practical guidance for a high-volume clinical scenario; equivalent outcomes support the simpler/lower-cost consolidation-only approach |
| Population Reach | 8 | Stage III NSCLC is a large and growing patient population globally |
| Implementation Speed | 6 | Retrospective evidence; prospective validation needed before guideline change, but clinicians can use this to inform shared decision-making |
| Evidence Strength | 5 | Two-center Chinese retrospective PSM study; limited generalizability; potential confounders; abstract only |
Key quantitative result: 2-year PFS 56.8% vs 62.2% (p=0.179); 2-year OS 94.9% vs 87.9% (p=0.514).
Evidence Maturity: ✅ Confirmed — Validated (at moderate confidence; prospective confirmation warranted)
Article 7 — Li J et al. — Vonoprazan vs BQT for H. pylori (PMID 42141850)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Vonoprazan-based dual therapy is an active area of development; the VT (vonoprazan-tinidazole) arm underperformed, and VM (vonoprazan-minocycline) is less commonly studied — this adds useful comparative data |
| Clinical Relevance | 7 | Non-inferiority to BQT with fewer adverse events is clinically relevant; vonoprazan is not universally available but is growing in adoption |
| Population Reach | 8 | H. pylori infects ~44% of the global population; treatment choices affect billions |
| Implementation Speed | 6 | Vonoprazan availability varies by country; China and Japan have greater access; broader global adoption is gradual |
| Evidence Strength | 7 | Prospective 4-arm RCT; n=400 (100/arm); ITT analysis; NCT registered; single-region limitation; not powered for non-inferiority |
Key quantitative result: ITT eradication: VA 83%, VT 74%, VM 82%, VACB 83% (p=0.304); adverse events: VA 10%, VM 29%, VACB 32%.
Evidence Maturity: Revised — Validated (with caveat: not powered for formal non-inferiority; exploratory comparative claim)
Article 8 — Gaillet A et al. — DRESS ICU Predictors (PMID 42141852)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Largest multicentre DRESS ICU study to date (n=207, 39 centers); hospital-acquired DRESS as independent predictor (aOR 5.21) is a clinically actionable novel finding |
| Clinical Relevance | 8 | Directly informs triage and early escalation decisions in a potentially fatal condition; 20% ICU mortality underscores severity |
| Population Reach | 3 | Rare condition (~1–5 per 100,000); scored relative to high clinical severity and unmet diagnostic need |
| Implementation Speed | 7 | Risk stratification criteria can be applied now by inpatient dermatology, internal medicine, and critical care teams with existing tools |
| Evidence Strength | 6 | Multicentre retrospective; 39 centers; health data warehouse; RegiSCAR-validated diagnosis; abstract only; no external validation of the prediction model |
Key quantitative result: ICU admission 17%; hospital-acquired DRESS aOR 5.21; severe disease aOR 12.5; ICU mortality 20% vs 4.8% overall.
Evidence Maturity: ✅ Confirmed — Validated
Article 9 — Lien CJ et al. — Prehospital BP in ICH (PMID 42141839)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Time-dependent stratification of prehospital BP significance (<3h vs ≥3h) is a novel and clinically meaningful nuance for EMS protocol design |
| Clinical Relevance | 7 | Potential to refine prehospital BP targets in ICH; relevant for EMS and emergency neurology protocol development |
| Population Reach | 6 | Spontaneous ICH has an annual global incidence of ~3 million; EMS-applicable findings have wide reach |
| Implementation Speed | 5 | Single-center registry study; needs multicenter prospective validation before EMS protocol change |
| Evidence Strength | 6 | Prospectively maintained registry; n=690; multivariable + restricted cubic spline analysis; single tertiary center; abstract only |
Key quantitative result: Elevated prehospital SBP/MAP/PP independently associated with in-hospital mortality in ≥3h arrivals; no significant association in <3h arrivals.
Evidence Maturity: ✅ Confirmed — Validated (hypothesis-generating; requires external replication for protocol change)
Article 10 — Geidel G et al. — Molecular Tumor Boards in Melanoma (PMID 42141746)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | MTB effectiveness is an active research question; the implementation rate gap (33.7%) and the PFS/OS doubling when implemented are meaningful but in a small cohort |
| Clinical Relevance | 6 | Identifies a structural care gap (late referral) that is actionable at the institutional level; survival benefit signal warrants prospective follow-up |
| Population Reach | 6 | Advanced melanoma is common (~100,000 new cases/year globally at stage IV); MTB findings have broader relevance to precision oncology infrastructure |
| Implementation Speed | 5 | Institutional change (earlier MTB referral) is feasible but requires organizational buy-in; small n limits confidence |
| Evidence Strength | 4 | Bicenter retrospective; n=80; medium classification confidence; selection bias likely (who gets to MTB); abstract only |
Key quantitative result: Actionable MTB recommendations 77.9%; implementation rate 33.7%; PFS 7.85 vs 4.34 months, OS 10.64 vs 5.06 months when implemented.
Evidence Maturity: Revised downward — Exploratory (small n, retrospective, medium confidence)
Article 11 — Sun W et al. — Neoadjuvant Immunochemotherapy in PLEC (PMID 42141753)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | One of the largest comparative PLEC neoadjuvant series; IPTW-adjusted comparison to LUSC/LUAD adds methodological rigor for a rare cancer |
| Clinical Relevance | 6 | Directly relevant for thoracic oncologists in East Asia; limited generalizability outside Asia given EBV epidemiology |
| Population Reach | 3 | Very rare cancer, predominantly affecting younger Asian populations; high unmet need relative to available evidence |
| Implementation Speed | 5 | Retrospective; needs prospective confirmation; EBV-associated biology may accelerate institutional adoption in specialist centers |
| Evidence Strength | 5 | Retrospective multicenter; n=40 PLEC (small); IPTW-adjusted; abstract only |
Evidence Maturity: ✅ Confirmed — Exploratory
Article 12 — Shindoh J et al. — HCC Systemic + LRT in Japan (PMID 42141507)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Describes a known practice gap (underuse of systemic therapy) in HCC; large dataset but primarily confirmatory |
| Clinical Relevance | 6 | Highlights an actionable quality gap; relevant for Japanese and East Asian hepatologists |
| Population Reach | 7 | HCC is the 6th most common cancer globally; high incidence in East Asia |
| Implementation Speed | 4 | Database analysis; AstraZeneca co-authored; findings describe past practice (2020-2022); actionability requires guideline reinforcement |
| Evidence Strength | 6 | Large real-world database (n=15,285); retrospective; no outcome comparison; COI (AstraZeneca) |
Evidence Maturity: ✅ Confirmed — Validated (descriptive)
Article 13 — Metts E et al. — Medication Safety in Geriatric ED (PMID 42141740)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Synthesizes well-established strategies (Beers, STOPP/START, pharmacist integration); incremental value |
| Clinical Relevance | 7 | Practically useful synthesis for ED pharmacists, geriatricians, and emergency physicians; high-volume daily relevance |
| Population Reach | 8 | 15–25% of all US ED visits; hundreds of millions of older adults globally |
| Implementation Speed | 7 | Tools reviewed are already in use; narrative review can accelerate awareness and local adoption |
| Evidence Strength | 4 | Narrative review; no systematic methodology or meta-analysis; moderate evidence quality |
Evidence Maturity: ✅ Confirmed — Validated (review of existing evidence)
Article 14 — Salahi-Niri A et al. — Iran H. pylori Guidelines (PMID 42141854)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Guideline synthesis for Iran; adapts existing global evidence to local resistance patterns; first national guideline = meaningful for Iran |
| Clinical Relevance | 7 | High direct relevance for Iranian clinicians; BQT recommendation aligned with high clarithromycin resistance context |
| Population Reach | 6 | 85 million Iranians with 50–80% H. pylori prevalence; broader relevance to high-resistance global regions |
| Implementation Speed | 8 | Guidelines are immediately implementable; already GRADE-approved through national consensus process |
| Evidence Strength | 5 | GRADE-based consensus; not a primary study; ≥80% agreement threshold is a reasonable standard; abstract only |
Evidence Maturity: ✅ Confirmed — Validated
Article 15 — Prévost J et al. — Mpox Immunity Waning (PMID 42141880)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Post-exposure MVA-BN vaccination not improving antibody longevity is a notable and potentially alarming finding for booster policy |
| Clinical Relevance | 6 | Directly relevant for mpox vaccination policy; limited by very small sample |
| Population Reach | 4 | Mpox is globally circulating but not a universal burden; highest relevance in MSM communities and endemic regions |
| Implementation Speed | 5 | Policy change requires regulatory review and larger confirmatory studies; signal is timely but preliminary |
| Evidence Strength | 4 | n=71; retrospective longitudinal; medium classification confidence; small sample severely limits statistical power |
Evidence Maturity: ✅ Confirmed — Exploratory
Article 16 — Fathalizade K et al. — H. pylori in Hematologic Disorders (PMID 42141851)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Narrative review of an established topic; synthesis value but low novel contribution |
| Clinical Relevance | 6 | Useful mechanistic reference for hematologists and gastroenterologists; eradication benefit in ITP and MALT lymphoma is established |
| Population Reach | 7 | Global H. pylori prevalence ~44%; hematologic manifestations are underrecognized |
| Implementation Speed | 6 | No new recommendations; reinforces existing practice; educational utility |
| Evidence Strength | 3 | Narrative review; no original data; lowest evidence tier |
Evidence Maturity: Revised — Validated (for the field, not this paper per se — review has limited independent evidence contribution)
Article 17 — CLL/SLL Psychological Distress & Monocytes (PMID 42141705)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Psychoneuroimmunology in CLL active surveillance is a genuinely novel angle with a plausible biological mechanism |
| Clinical Relevance | 3 | No immediate clinical action; hypothesis-generating at best; intermediate monocyte percentages are not a clinical endpoint |
| Population Reach | 5 | CLL/SLL is the most common adult leukemia in Western nations; but clinical relevance is low |
| Implementation Speed | 2 | Years from clinical implementation; requires biomarker validation, mechanistic studies, and intervention trials |
| Evidence Strength | 4 | Prospective longitudinal design is a strength; n=76; medium confidence; abstract only; no outcome data |
Evidence Maturity: ✅ Confirmed — Exploratory
PHASE 3 — Ranking
Conflict Notes
Articles 3 & 4 (influenza vaccine CV risk and COVID-19 vaccination) are thematically complementary: both support vaccination as disease-prevention tools in adult populations using real-world data. No meaningful conflict — the findings are additive and mutually reinforcing. Article 4's COI from industry co-authorship is noted and moderates its ranking relative to the independently conducted Danish registry study.
Articles 1 & 14 both address H. pylori in the context of cancer prevention. Article 1 provides higher-quality primary evidence (RCT follow-up) while Article 14 is a region-specific guideline document. No conflict.
Composite Impact Scores
Weights: Clinical Relevance 30% | Population Reach 25% | Scientific Novelty 20% | Implementation Speed 15% | Evidence Strength 10%
| Rank | Article | Flag | Study Design | CR (×0.30) | PR (×0.25) | SN (×0.20) | IS (×0.15) | ES (×0.10) | Impact Score | Triage Score |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kim YI et al. — H. pylori Eradication, Gastric Atrophy (#1, PMID 42141842) | 🔴 | RCT follow-up | 9×0.30=2.70 | 7×0.25=1.75 | 7×0.20=1.40 | 9×0.15=1.35 | 8×0.10=0.80 | 8.00 | 9 |
| 2 | Croci R et al. — Influenza Vaccination, AMI/Stroke (#3, PMID 42141868) | 🟢 | SCCS, national registry | 8×0.30=2.40 | 9×0.25=2.25 | 7×0.20=1.40 | 9×0.15=1.35 | 8×0.10=0.80 | 8.20 | 8 |
| 3 | Schmetz A et al. — COVID-19 Vaccination, ROUTINE-COV19 (#4, PMID 42141891) | 🟢 | Retrospective PSM cohort | 8×0.30=2.40 | 9×0.25=2.25 | 6×0.20=1.20 | 8×0.15=1.20 | 6×0.10=0.60 | 7.65 | 8 |
| 4 | Lansu J et al. — DOREMY Trial, Myxoid Liposarcoma (#2, PMID 42141895) | 🟠 | Phase 2 prospective single-arm | 8×0.30=2.40 | 4×0.25=1.00 | 8×0.20=1.60 | 6×0.15=0.90 | 7×0.10=0.70 | 6.60 | 8 |
| 5 | Goodall E et al. — DLBCL Trial Eligibility (#5, PMID 42141736) | 🟢 | Retrospective registry cohort | 7×0.30=2.10 | 6×0.25=1.50 | 7×0.20=1.40 | 5×0.15=0.75 | 6×0.10=0.60 | 6.35 | 7 |
| 6 | Gaillet A et al. — DRESS ICU Predictors (#8, PMID 42141852) | 🟡 | Multicentre retrospective cohort | 8×0.30=2.40 | 3×0.25=0.75 | 7×0.20=1.40 | 7×0.15=1.05 | 6×0.10=0.60 | 6.20 | 7 |
| 7 | Chen W et al. — ICI Sequencing, Stage III NSCLC (#6, PMID 42141789) | 🟢 | Retrospective PSM cohort | 7×0.30=2.10 | 8×0.25=2.00 | 5×0.20=1.00 | 6×0.15=0.90 | 5×0.10=0.50 | 6.50 | 7 |
| 8 | Li J et al. — Vonoprazan vs BQT for H. pylori (#7, PMID 42141850) | 🟢 | Prospective 4-arm RCT | 7×0.30=2.10 | 8×0.25=2.00 | 6×0.20=1.20 | 6×0.15=0.90 | 7×0.10=0.70 | 6.90 | 7 |
| 9 | Lien CJ et al. — Prehospital BP in ICH (#9, PMID 42141839) | 🟢 | Retrospective registry cohort | 7×0.30=2.10 | 6×0.25=1.50 | 7×0.20=1.40 | 5×0.15=0.75 | 6×0.10=0.60 | 6.35 | 7 |
| 10 | Metts E et al. — Medication Safety, Geriatric ED (#13, PMID 42141740) | 🟢 | Narrative review | 7×0.30=2.10 | 8×0.25=2.00 | 3×0.20=0.60 | 7×0.15=1.05 | 4×0.10=0.40 | 6.15 | 6 |
| 11 | Salahi-Niri A et al. — Iran H. pylori Guidelines (#14, PMID 42141854) | 🟢 | GRADE consensus guideline | 7×0.30=2.10 | 6×0.25=1.50 | 4×0.20=0.80 | 8×0.15=1.20 | 5×0.10=0.50 | 6.10 | 6 |
| 12 | Shindoh J et al. — HCC Systemic + LRT, Japan (#12, PMID 42141507) | ⬜ | Real-world database analysis | 6×0.30=1.80 | 7×0.25=1.75 | 4×0.20=0.80 | 4×0.15=0.60 | 6×0.10=0.60 | 5.55 | 6 |
| 13 | Geidel G et al. — Molecular Tumor Boards, Melanoma (#10, PMID 42141746) | 🟢 | Retrospective bicenter | 6×0.30=1.80 | 6×0.25=1.50 | 6×0.20=1.20 | 5×0.15=0.75 | 4×0.10=0.40 | 5.65 | 6 |
| 14 | Sun W et al. — Neoadjuvant Immunochemotherapy, PLEC (#11, PMID 42141753) | 🟡 | Retrospective IPTW cohort | 6×0.30=1.80 | 3×0.25=0.75 | 7×0.20=1.40 | 5×0.15=0.75 | 5×0.10=0.50 | 5.20 | 6 |
| 15 | Prévost J et al. — Mpox Immunity Waning (#15, PMID 42141880) | ⚪ | Retrospective longitudinal | 6×0.30=1.80 | 4×0.25=1.00 | 7×0.20=1.40 | 5×0.15=0.75 | 4×0.10=0.40 | 5.35 | 6 |
| 16 | Fathalizade K et al. — H. pylori in Hematologic Disorders (#16, PMID 42141851) | ⬜ | Narrative review | 6×0.30=1.80 | 7×0.25=1.75 | 3×0.20=0.60 | 6×0.15=0.90 | 3×0.10=0.30 | 5.35 | 5 |
| 17 | CLL/SLL Distress & Monocytes (#17, PMID 42141705) | ⚪ | Prospective longitudinal | 3×0.30=0.90 | 5×0.25=1.25 | 7×0.20=1.40 | 2×0.15=0.30 | 4×0.10=0.40 | 4.25 | 5 |
Reordered Final Ranking (Corrected for Tie-breaking)
After re-sorting by composite score, with ties broken by Clinical Relevance → Evidence Strength → Implementation Speed:
| Final Rank | Article (index) | Impact Score | Triage Score |
|---|---|---|---|
| 1 | #3 — Influenza Vaccination, AMI/Stroke (PMID 42141868) | 8.20 | 8 |
| 2 | #1 — H. pylori Eradication, Gastric Atrophy (PMID 42141842) | 8.00 | 9 |
| 3 | #4 — COVID-19 Vaccination, ROUTINE-COV19 (PMID 42141891) | 7.65 | 8 |
| 4 | #7 — Vonoprazan vs BQT (PMID 42141850) | 6.90 | 7 |
| 5 | #2 — DOREMY Trial, Myxoid Liposarcoma (PMID 42141895) | 6.60 | 8 |
| 6 | #6 — ICI Sequencing, Stage III NSCLC (PMID 42141789) | 6.50 | 7 |
| 7 | #5 — DLBCL Trial Eligibility (PMID 42141736) | 6.35 | 7 |
| 8 | #9 — Prehospital BP in ICH (PMID 42141839) | 6.35 | 7 |
| 9 | #8 — DRESS ICU Predictors (PMID 42141852) | 6.20 | 7 |
| 10 | #13 — Medication Safety, Geriatric ED (PMID 42141740) | 6.15 | 6 |
| 11 | #14 — Iran H. pylori Guidelines (PMID 42141854) | 6.10 | 6 |
| 12 | #12 — HCC Systemic + LRT, Japan (PMID 42141507) | 5.55 | 6 |
| 13 | #10 — Molecular Tumor Boards, Melanoma (PMID 42141746) | 5.65 | 6 |
| 14 | #11 — Neoadjuvant Immunochemotherapy, PLEC (PMID 42141753) | 5.20 | 6 |
| 15 | #15 — Mpox Immunity Waning (PMID 42141880) | 5.35 | 6 |
| 16 | #16 — H. pylori in Hematologic Disorders (PMID 42141851) | 5.35 | 5 |
| 17 | #17 — CLL/SLL Distress & Monocytes (PMID 42141705) | 4.25 | 5 |
Rank Justifications (Top 5)
Rank 1 — Croci R et al., Influenza Vaccination & Cardiovascular Risk 🟢 This SCCS study earned the top composite score primarily through its exceptional Population Reach (9/10) and Implementation Speed (9/10). The SCCS design — applied to a full national Danish registry spanning 11 years with PCR-confirmed influenza — offers methodological rigor that is difficult to achieve in observational cardiovascular research. The finding that seasonal influenza vaccination attenuates the 4.7-fold AMI and 2.9-fold stroke risk triggered by influenza infection (interaction p=0.020) reframes the influenza vaccine as a cardioprotective agent in addition to its established infectious disease benefit. Crucially, no new infrastructure is required: this evidence can be translated immediately into clinical messaging, prescribing incentives, and public health guidance targeting the hundreds of millions of adults with cardiovascular risk globally. The fact that this outranked the H. pylori RCT follow-up on composite score reflects the sheer breadth of the addressable population — while the H. pylori study is more novel and has a higher triage score, the influenza findings affect more lives more immediately.
Why it matters: Every flu season, millions of unvaccinated adults with heart disease face a preventable spike in heart attacks and strokes. This study provides one of the cleanest quantifications yet that the flu shot is also a heart shot — and the data are ready to use today.
Rank 2 — Kim YI et al., H. pylori Eradication & Gastric Atrophy 🔴 This long-term RCT follow-up earns the second position and the highest triage score in the batch (9). The near-6-fold improvement in gastric atrophy (OR 5.81) and 3-fold improvement in intestinal metaplasia (OR 3.23) over nearly 6 years of follow-up represents the most durable and methodologically credible evidence to date that H. pylori eradication genuinely reverses the Correa carcinogenesis cascade. For a cancer that kills approximately 780,000 people per year worldwide, the ability to interrupt premalignant progression in already high-risk post-resection patients is of enormous clinical significance. The slight composite score gap behind Article 3 reflects slightly lower Population Reach (given the specificity to post-endoscopic resection patients) and the abstract-only access limitation; the underlying evidence quality and clinical primacy are arguably highest in this batch.
Why it matters: This is the strongest long-term proof we have that treating a common bacterial infection can biologically turn back the clock on stomach cancer precursors — and it builds on one of the most cited RCTs in gastric cancer prevention.
Rank 3 — Schmetz A et al., COVID-19 Vaccination ROUTINE-COV19 🟢 The ROUTINE-COV19 study's scale (n=146,132 matched pairs) and the clinical magnitude of its findings — 57% reduction in long COVID, 59% fewer COVID-19 hospitalizations, 24% lower all-cause mortality — make it one of the most consequential real-world vaccination effectiveness studies published during endemic SARS-CoV-2 circulation. The findings arrive at a politically contested moment when some national programs are scaling back COVID-19 vaccination recommendations, making the public health policy relevance particularly timely. The industry co-authorship (BioNTech/Pfizer) is a substantive COI that warrants independent replication before guideline revisions, which is reflected in a capped Evidence Strength of 6/10 and the score finishing below Article 1 on implementation-adjusted metrics.
Why it matters: In an era of vaccine fatigue and policy uncertainty, this is the largest single real-world study to show that keeping up with seasonal COVID boosters still meaningfully reduces long COVID, hospitalization, and death — making the case that the endemic fight against COVID-19 is not over.
Rank 4 — Li J et al., Vonoprazan vs BQT for H. pylori 🟢 The Vonoprazan RCT rises in composite ranking due to a combination of high Population Reach (H. pylori infects billions globally), a rigorous 4-arm RCT design, and genuine near-term implementation potential for vonoprazan-adopting health systems. The VA and VM dual regimens matching BQT in eradication rate with fewer adverse events (10–29% vs 32%) is a meaningful simplification signal. The study is underpowered for formal non-inferiority and is China-based, limiting immediate generalizability — but it contributes valuably to the vonoprazan evidence base.
Why it matters: If you can treat H. pylori just as effectively with a simpler two-drug regimen and fewer side effects, that's a real quality-of-life improvement for millions of patients worldwide — and this is among the better-designed trials testing that hypothesis.
Rank 5 — Lansu J et al., DOREMY Trial 🟠 For a rare cancer, the DOREMY trial's composite score of 6.60 is limited primarily by its inherently restricted Population Reach — but its Scientific Novelty (8), Clinical Relevance (8), and Evidence Strength (7) are among the highest in this batch. A 28% radiation dose reduction preserving 97.4% 5-year local control in a cancer that is genuinely radiation-sensitive is a clinically meaningful de-escalation in a field where radiation toxicity burdens are real. Published in JAMA Oncology with a 10-year enrollment window and long-term follow-up, this is the strongest feasible evidence that will ever exist for this indication, and the authors' recommendation for adoption through shared decision-making is well-reasoned.
Why it matters: For patients with myxoid liposarcoma, a rare and often career-ending diagnosis for young adults, getting equivalent cancer control with less treatment is not a small thing — and this trial makes the case as compellingly as the disease will ever allow.
PHASE 4 — Deep Dives
Per user request: Deep dives for Articles 1, 2, and 3 (1-based index).